FX.co ★ Silo Pharma Enters Exclusive License Agreement For SPC-15 Drug Candidate - Quick Facts

Silo Pharma (SILO) has announced the signing of an exclusive, global license agreement with Columbia University aimed at advancing the development, manufacturing, and commercialization of its leading drug candidate, SPC-15. This intranasal treatment targets stress-induced affective disorders and PTSD. The company is currently finalizing the necessary steps to submit an Investigational New Drug (IND) application to the FDA to initiate first-in-human clinical studies.

"We believe that securing the exclusive license agreement for our SPC-15 product represents a crucial milestone for Silo Pharma, potentially enhancing shareholder value pending FDA approval," stated Silo Pharma CEO Eric Weisblum.